[1]刘建伟,郑爱民.早期非小细胞肺癌局部治疗研究进展[J].介入放射学杂志,2023,32(05):508-511.
　LIU Jianwei,ZHENG Aimin..Research progress in local treatment of early non-small cell lung cancer[J].journal interventional radiology,2023,32(05):508-511.

点击复制

早期非小细胞肺癌局部治疗研究进展()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［1］ Siegel RL，Miller KD，Jemal A.Cancer statistics，2019［J］. CA Cancer J Clin， 2019，69：7- 34.
［2］ Sung H， Ferlay J，Siegel RL，et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209- 249.
［3］ 刘宝东． 非小细胞肺癌射频消融热点问题探讨［J］． 介入放射学杂志， 2018， 27：1013- 1017．
［4］ 胡鹏程．早期非小细胞肺癌外科手术治疗的研究进展［J］． 山东医药， 2019， 59：107- 110．
［5］ 周 坤． 电视辅助胸腔镜下解剖性肺叶切除术与亚肺叶切除术分别联合纵隔淋巴结清扫术治疗早期非小细胞肺癌对比研究［J］． 当代临床医刊， 2021， 34：8- 10．
［6］ Lim TY，Park S，Kang CH. A meta- analysis comparing lobectomy versus segmentectomy in stage Ⅰ non- small cell lung cancer［J］. Korean J Thorac Cardiovasc Surg， 2019， 52： 195- 204.
［7］ Zhang H，Liu C，Tan Z，et al. Segmentectomy versus wedge resection for stage Ⅰ non- small cell lung cancer： a meta- analysis［J］. J Surg Res， 2019， 243： 371- 379.
［8］ 谢振城，陈滚新，李晓东，等． 胸腔镜下肺楔形切除术与肺段切除术治疗早期肺癌的临床效果比较［J］． 中外医学研究， 2021，19：58- 61．
［9］ Dai C，Shen J，Ren Y，et al. Choice of surgical procedure for patients with non- small- cell lung cancer≤1 cm or＞1 to 2 cm among lobectomy， segmentectomy， and wedge resection： a population- based study［J］. J Clin Oncol， 2016， 34： 3175- 3182.
［10］ Tsutani Y，Kagimoto A，Handa Y，et al. Wedge resection versus segmentectomy in patients with stage Ⅰ non- small- cell lung cancer unfit for lobectomy［J］. Jpn J Clin Oncol， 2019， 49： 1134- 1142.
［11］ Bott MJ，Crabtree T. Treatment of stage Ⅰ lung cancer in high- risk and inoperable patients：SBRT vs. RFA vs. sublobar resection［J］. Ann Cardiothorac Surg，2014，3：167- 169.
［12］ Ettinger DS，Wood DE，Aisner DL，et al. NCCN guidelines insights： non- small cell lung cancer， version 2.2021［J］. J Natl Compr Canc Netw， 2021， 19： 254- 266.
［13］ Schneider BJ，Daly ME，Kennedy EB， et al. Stereotactic body radiotherapy for early- stage non- small- cell lung cancer： American society of clinical oncology endorsement of the american society for radiation oncology evidence- based guideline［J］. J Clin Oncol， 2018， 36： 710- 719.
［14］ 栾宏辉．肺癌患者立体定向放射治疗的有效性及对患者外周血IL- 12、IL- 15水平的影响［J］． 中国医学创新， 2021， 18：146- 149．
［15］ Zhang B，Zhu F，Ma X，et al. Matched- pair comparisons of stereotactic body radiotherapy（SBRT） versus surgery for the treatment of early stage non- small cell lung cancer： a systematic review and meta- analysis［J］. Radiother Oncol， 2014， 112： 250- 255.
［16］ Cornwell LD， Echeverria AE， Samuelian J， et al. Video- assisted thoracoscopic lobectomy is associated with greater recurrence- free survival than stereotactic body radiotherapy for clinical stage Ⅰ lung cancer［J］. J Thorac Cardiovasc Surg， 2018， 155： 395- 402.
［17］ Detillon DDEMA，Aarts MJ，De Jaeger K， et al. Video- assisted thoracic lobectomy versus stereotactic body radiotherapy for stage Ⅰ nonsmall cell lung cancer in elderly patients： a propensity matched comparative analysis［J］. Eur Respir J， 2019，53 ：1801561.
［18］ Chang JY，Senan S，Paul MA，et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non- small- cell lung cancer： a pooled analysis of two randomised trials［J］. Lancet Oncol， 2015， 16： 630- 637.
［19］ 田 慧，叶 欣． 微波消融治疗早期非小细胞肺癌现状［J］． 介入放射学杂志， 2018， 27：1102- 1106．
［20］ 赵真真，王忠敏，茅爱武． 非小细胞肺癌的介入治疗现状［J］． 介入放射学杂志， 2014 ，23：272- 276．
［21］ 韩晓颖，杨 霞，叶 欣，等． CT导引微波消融治疗高龄老人早期周围型非小细胞肺癌32例［J］． 介入放射学杂志， 2018， 27：1051- 1055．
［22］ 邹旭公，李晓群，陈 源，等． C臂CT引导经皮穿刺射频消融治疗不可切除Ⅰa期非小细胞肺癌［J］． 介入放射学杂志， 2018， 27：1056- 1059．
［23］ 韩景奇，张传玉，李 涌，等． 早期非小细胞肺癌CT引导射频消融治疗60例临床分析［J］． 介入放射学杂志， 2015， 24：414- 417．
［24］ Kim SR，Han HJ，Park SJ，et al. Comparison between surgery and radiofrequency ablation for stage Ⅰ non- small cell lung cancer［J］. Eur J Radiol， 2012， 81： 395- 399.
［25］ 侯立泳，高兴强，王 永，等． 经皮微波消融与胸腔镜肺叶切除术治疗Ⅰ期非小细胞肺癌的疗效［J］． 介入放射学杂志， 2019， 28：851- 854．
［26］ Yao W，Lu M，Fan W，et al. Comparison between microwave ablation and lobectomy for stage Ⅰ non- small cell lung cancer： a propensity score analysis［J］. Int J Hyperthermia， 2018， 34： 1329- 1336.
［27］ Li M，Yang X，Chen Y，et al. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1- 3N0M0 non- small cell lung cancer： a systematic review and meta- analysis［J］. Onco Targets Ther， 2017， 10： 2885- 2892.
［28］ Ijsseldijk MA，Shoni M，Siegert C，et al. Oncologic outcomes of surgery versus sbrt for non- small- cell lung carcinoma： a systematic review and meta- analysis［J］. Clin Lung Cancer， 2021， 22： e235- e292.
［29］ Wen SW，Han L，Lv HL，et al. A propensity- matched analysis of outcomes of patients with clinical stage Ⅰ non- small cell lung cancer treated surgically or with stereotactic radiotherapy： a meta- analysis［J］. J Invest Surg， 2019， 32： 27- 34.
［30］ Dong B， Zhu X， Jin J， et al. Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1- 2N0M0 non- small cell lung cancer with tumor size≤5 cm： a propensity score matching analysis［J］. J Thorac Dis， 2020， 12： 5934- 5954.
［31］ Tamura M，Matsumoto I，Tanaka Y，et al. Comparison between stereotactic radiotherapy and sublobar resection for non- small cell lung cancer［J］. Ann Thorac Surg， 2019， 107： 1544- 1550.
［32］ Haasbeek CJ，Lagerwaard FJ，Slotman BJ，et al. Outcomes of stereotactic ablative radiotherapy for centrally located early- stage lung cancer［J］. J Thorac Oncol， 2011， 6： 2036-2043.
［33］ Bezjak A，Paulus R，Gaspar LE，et al. Safety and efficacy of a five- fraction stereotactic body radiotherapy schedule for centrally located non- small- cell lung cancer： NRG oncology/RTOG 0813 trial［J］. J Clin Oncol， 2019， 37： 1316- 1325.
［34］ Chan MV，Huo YR，Cao C，et al. Survival outcomes for surgical resection versus CT- guided percutaneous ablation for stage Ⅰ non- small cell lung cancer（NSCLC）： a systematic review and meta- analysis［J］. Eur Radiol， 2021， 31： 5421- 5433.
［35］ Chen S，Yang S，Xu S，et al. Comparison between radiofrequency ablation and sublobar resections for the therapy of stage Ⅰ non- small cell lung cancer：a meta- analysis［J］. Peer J， 2020， 8：e9228.
［36］ Zeng C，Lu J，Tian Y，et al. Thermal ablation versus wedge resection for stage Ⅰ non- small cell lung cancer based on the eighth edition of the TNM classification： a population study of the US SEER database［J］. Front Oncol，2020，10：571684.
［37］ Bi N，Shedden K，Zheng X，et al. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage Ⅰ non- small cell lung cancer：a systemic review and pooled analysis［J］. Int J Radiat Oncol Biol Phys， 2016， 95： 1378- 1390.
［38］ Ager BJ，Wells SM，Gruhl JD，et al. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early- stage non- small cell lung cancer［J］. Lung Cancer， 2019， 138： 6- 12.
［39］ Lam A，Yoshida EJ，Bui K，et al. A national cancer database analysis of radiofrequency ablation versus stereotactic body radiotherapy in early- stage non- small cell lung cancer［J］. J Vasc Interv Radiol， 2018， 29： 1211- 1217.